Although novel therapies include vascular endothelial growth factor, tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, all of which have shown significant activity against RCC with metastases, no treatment has been established for sarcomatoid RCC and few studies have analyzed this histological variant. This evidence concerns the gene MTOR and renal cell carcinoma.